Quick Takeaways
- Roivant Sciences Ltd. filed SCHEDULE 13D/A for Arbutus Biopharma Corp Common Shares, without par value (ABUS).
- Disclosed ownership: 20%.
- Date of event: 21 Feb 2025.
Roivant Sciences Ltd. - 21 Feb 2025 SCHEDULE 13D/A Report for Arbutus Biopharma Corp Common Shares, without par value (ABUS)
- Filing Manager
- Roivant Sciences Ltd.
- Reporting Manager
- Roivant Sciences Ltd.
- Symbol
- ABUS
- Shares outstanding
- 189,499,815 shares
- Disclosed Ownership
- 38,847,462 shares
- Ownership
- 20%
- Form type
- SCHEDULE 13D/A
- Filing time
- 25 Feb 2025, 07:19:33 UTC
- Date of event
- 21 Feb 2025
- Previous filing
- 18 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Roivant Sciences Ltd. disclosed 20% ownership in Arbutus Biopharma Corp Common Shares, without par value (ABUS) on 21 Feb 2025."
What Changed
- Previous schedule filing date: 18 Feb 2025.
- Current filing was accepted on 25 Feb 2025, 07:19.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 20% | 38,847,462 | 38,847,462 | 0 | /s/ Keyur Parekh | Keyur Parekh, Authorized Signatory | 0001635088 |